Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo®) in Subjects With Recurrent or Progressive Glioblastoma

NCT04006119 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT04006119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04006119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo®) in Subjects With Recurrent or Progressive Glioblastoma
Lead sponsor
Alaunos Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
August 1, 2019
Completion date
August 5, 2021
Enrollment
40 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma